About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pick Up Service

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

600.22 -7.71 (-1.27%)

Streaming Delayed Price Updated: 10:55 AM EDT, Jun 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

63 64 Next >

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗

March 04, 2024

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Via InvestorPlace

Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture? ↗

March 01, 2024

Via Benzinga

The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts ↗

February 27, 2024

Via Benzinga

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

February 26, 2024

Via Benzinga

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗

February 22, 2024

Via Benzinga

2 No-Brainer Biotech Stocks to Buy Right Now ↗

February 21, 2024

These stocks are used to beating the market.

Via The Motley Fool

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

February 23, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

February 21, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 2/20 Morning Trading

February 20, 2024

Via Investor Brand Network

$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today ↗

February 06, 2024

Via Benzinga

Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests ↗

February 20, 2024

The FDA put studies in eczema and asthma treatment on clinical hold.

Via Investor's Business Daily

Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling ↗

February 20, 2024

The Nasdaq 100 closed lower by over 150 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

2 Top Growth Stocks to Buy With $1,000 Right Now ↗

February 18, 2024

Even a modest starting investment in the right stocks could pay off in the years ahead.

Via The Motley Fool

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

February 16, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 12, 2024

Via Benzinga

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys? ↗

February 09, 2024

There's room for multiple winners in the fast-growing weight-loss market.

Via The Motley Fool

The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition ↗

February 06, 2024

Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.

Via InvestorPlace

Topics Artificial Intelligence

Regeneron Announces Investor Conference Presentations

February 06, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast ↗

February 06, 2024

4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.

Via Benzinga

Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗

February 06, 2024

Via Benzinga

Stock-Split Watch: Could These 2 Market-Beaters Be Next? ↗

February 06, 2024

Investors might continue bidding up shares of these companies regardless.

Via The Motley Fool

Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? ↗

February 05, 2024

4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity.

Via Benzinga

Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗

February 02, 2024

The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.

Via Benzinga

Topics Economy

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗

February 02, 2024

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.

Via Benzinga

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High ↗

February 02, 2024

Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products.

Via Investor's Business Daily

Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year ↗

February 02, 2024

Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

63 64 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Sections

Services

Contact Information

Follow Us